Course : ACMG Genomics Case Conference May 2017
Genomic Diagnosis for Children with Developmental Delay/Intellectual Disability
Hosted by HudsonAlpha Institute for Biotechnology
Click Launch for details.
During The ACMG Genomics Case Conferences, a team from select institutions will present and lead discussions on an intriguing, complex and/or difficult patient case in the area of genomics. The primary focus of these case conferences will be on the adaptation of exome or genome sequencing technology in clinical care.
Developmental delay, intellectual disability, and related conditions (DD/ID) have considerable medical, financial, and psychological impacts on affected individuals and their families. As part of the Clinical Sequencing Exploratory Research (CSER) Consortium, we are sequencing children with intellectual and developmental disabilities that are refractory to standard diagnostic testing. Cases from this cohort will be presented, including those resulting in changes to medical management. Gene discovery and secondary findings will also be briefly discussed. Our experiences strongly support the value of large-scale sequencing as both a potent first-choice diagnostic tool and means to continually advance clinical and research progress related to DD/ID, especially when data are shared freely and rapidly.
This activity is supported by an unrestricted educational grant from QIAGEN Bioinformatics and the Ingenuity Clinical Decision Support Platform.
Please Click Here for More Course Information
Educational Credits Available
Amount of Credits: 1 (CME)
ACMG Members and ACMG Trainees free
ACMG Member with educational credits ($15)
Non-members with educational credits ($55)
At the conclusion of the series, participants should be able to:
1. Describe the clinical utility of whole exome/whole genome sequencing tests
2. Identify clinical indications for whole exome/whole genome sequencing
3. List determinants used to assess the probability of a variant’s pathogenicity
3. Elaborate on the importance of pre-test counseling and consent
4. Describe the overall goals of the CSER project at HudsonAlpha
5. Identify changes in clinical management that can occur based on sequencing developmental delay/intellectual disability -affected individuals
6. Address implications of reporting secondary and incidental findings to unaffected participants